Triazolo-pyridines as anti-inflammatory compounds

Details Triazolo-pyridines as anti-inflammatory compounds Triazolo-pyridines as anti-inflammatory compounds

2004-02-11

2008-01-22

Seaman, Margaret D. (Department: 1625)

Organic compounds -- part of the class 532-570 series

Organic compounds

Heterocyclic carbon compounds containing a hetero ring...

Reexamination Certificate

active

07321040

ABSTRACT:
The present invention relates to novel triazolo-pyridines of the formulawherein X is >CH2, >NH, sulfur, >S═O, >SO2or oxygen; wherein said >CH2and >NH may optionally be substituted with a suitable substituent;R1is selected from the group consisting of hydrogen, (C1-C6)alkyl and other suitable substituents;R2is selected from the group consisting of hydrogen, (C1-C6)alkyl and other suitable substituents;s is an integer from 0-4;R3is R4, R5—(NR6)—, R5—S—, R5—(S═O)—, R5—(SO2)—, R5—SO2—NR6—, R5—(NR6)—SO2—, R5—O—, R5—(C═O)—, R5—(NR6)—(C═O)—, R5—(C═O)—NR6—, R5—O—(C═O)—, R5—(C═O)—O—, R5—CR7═CR8— or R5—C≡C—; such that the molecular weight of R3is less than 500 AMU, preferably less than 250 AMU;R4, R5and R6are each selected from the group consisting of hydrogen, (C1-C6)alkyl and other suitable substituents;or a pharmaceutically acceptable salt thereof;to intermediates for their preparation, to pharmaceutical compositions containing them and to their medicinal use. The compounds of the present invention are potent inhibitors of MAP kinases. They are useful in the treatment of inflammation, osteoarthritis, rheumatoid arthritis, cancer, reperfusion or ischemia in stroke or heart attack, autoimmune diseases and other disorders.

REFERENCES:
patent: 3050525 (1962-08-01), Bicking
patent: 3119742 (1964-01-01), Heimlich et al.
patent: 3492397 (1970-01-01), Peters et al.
patent: 3538214 (1970-11-01), Polli et al.
patent: 4060598 (1977-11-01), Groppenbächer et al.
patent: 4173626 (1979-11-01), Dempski et al.
patent: 5716955 (1998-02-01), Adams et al.
patent: 5716972 (1998-02-01), Adams et al.
patent: 6288062 (2001-09-01), Adams et al.
patent: 2004/0053958 (2004-03-01), Dombroski et al.
patent: 2004/0053959 (2004-03-01), Buzon, Sr. et al.
patent: 2004/0077682 (2004-04-01), Dombroski et al.
patent: 2004/0087615 (2004-05-01), Dombroski et al.
patent: 2004/0092547 (2004-05-01), Dombroski et al.
patent: 1 247 810 (2002-10-01), None
patent: WO 00/06563 (2000-02-01), None
patent: WO 00/31065 (2000-06-01), None
patent: WO 00/40243 (2000-07-01), None
patent: WO 00/41698 (2000-07-01), None
patent: WO 00/63204 (2000-10-01), None
patent: WO 01/57038 (2001-08-01), None
patent: WO 02/072576 (2002-09-01), None
patent: WO 02/072579 (2002-09-01), None
patent: WO 03/044021 (2003-05-01), None
patent: WO 04/020609 (2004-03-01), None
Zhou L. et al., “Inhibition of the CD40 Pathway of Monocyte Activation by Triazolopyrimidine”, Clinical Immunology 93(3):232-238 (1999).
Griswold D.E., et al., “Effect of Inhibitors of Eicosanoid Metabolism in Murine Collagen-Induced Arthritis”,Arthritis and Rheumatism, 31(11): 1406-1412, (1988).
Badger A.M., et al., “Protective Effect of SK&F 86002, a Novel Dual Inhibitor of Arachidonic Acid Metabolism, in Murine Models of Endotoxin Shock: Inhibition of Tumor Necrosis Factor as a Possible Mechanism of Action”,Circulatory Shock, 27:51-61 (1989).
Votta B.J., et al., “Cytokine Suppressive Anti-inflammatory Compounds Inhibit Bone Resorption In Vitro”,Bone, 15(5):533-538 (1994).
Lee J.C., et al., “Bicyclic Imidazoles as a Novel Class of Cytokine Biosynthesis Inhibitors”,Annals New York Academy of Sciences, 696:149-170 (1993).
Turner R.B., et al., “Association Between Interleukin-8 Concentration in Nasal Secretions and Severity of Symptoms of Experimental Rhinovirus Colds”,Clinical Infectious Diseases, 26:840-846 (1998).
Teran L.M., et al., “Role of Nasal Interleukin-8 in Neutrophil Recruitment and Activation in Children with Virus-Induced Asthma”,American Journal of Respiratory and Critical Care Medicine, 155:1362-1366 (1997).
Grünberg K., et al., “Experimental Rhinovirus 16 Infection. Effects on Cell Differentials and Soluble Markers in Sputum in Asthmatic Subjects”,American Journal of Respiratory and Critical Care Medicine, 156:609-616 (1997).
Zhu Z., et al., “Rhinovirus Stimulation of Interleukin-6 In Vivo and In Vitro. Evidence For Nuclear Factor κB-dependent Transcriptional Activation”,The Journal of Clinical Investigation, 97(2):421-430 (1996).
Subauste M.C., et al., “Infection of a Human Respiratory Epithelial Cell Line with Rhinovirus. Induction of Cytokine Release and Modulation of Susceptibility to Infection by Cytokine Exposure”,Journal of Clinical Investigation, 96:549-557 (1995).
Greene, T.W. et al., “The Role of Protective Groups in Organic Synthesis”,Protective Groups in Organic Synthesis, 2 Ed.:1-9 (1991).

Affiliated with

Also associated with

Rating

Triazolo-pyridines as anti-inflammatory compounds does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Triazolo-pyridines as anti-inflammatory compounds, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Triazolo-pyridines as anti-inflammatory compounds will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3962438